Human Organoids Market by Product (Pancreas, Kidney, Lung, GIT, Liver Models) Usabilty (Customized, Ready-To-Use), Application (Toxicity, Pathology, Personalized & Regenerative Medicine), Enduser (Pharma-Biotech, CROs, Academia) - Global Forecast to 2025

Publisher: MarketsandMarkets
Publication Date: December, 2020
Healthcare / Drugs
Pages: 175
Delivery Format: PDF

by Product (Pancreas, Kidney, Lung, GIT, Liver Models) Usabilty (Customized, Ready-To-Use), Application (Toxicity, Pathology, Personalized & Regenerative Medicine), Enduser (Pharma-Biotech, CROs, Academia)

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5%. Factors such as the technological advancements in the market are propelling the growth of the human orgnaoids market. Additionally, rising cases of transplants, investments from both private and public sectors are having affect in the growth of human organoids market. However, unfavorable reimbursement scenarios in some countries is hampering the growth of this market. The recent COVID-19 global pandemic has also impacted the human organoids market. Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns. This impact is expected to be short-term, and no adverse effects are to be foreseen after the market gradually reopens. “The kidney segment to witness the highest growth rate in human organoids market, by product, during the forecast period.” The kidney segment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the high prevalence of kidney diseases across major markets (resulting in a growing number of transplants procedures), the growing trend of increasing purchasing power of people, especially across emerging countries. “The developmental biology accounted for the largest share of the human orgnaoids market, by human organoids, in 2020.” The developmental biology segment accounted for the largest share of the human orgnaoids market in 2020. Technological advancements in the field of 3D bioprinting have shown huge potential for organ development as the culture time is very less compared to traditional methods of tissue culture. Patient-derived human organoid studies may accelerate medical research, creating new opportunities for tissue engineering and regenerative medicine and generating knowledge and tools for preclinical studies, including drug development and testing. “The pharmaceuticals & biotechnology companies segment accounted for the largest share of the human organoids, by end users, in 2020” Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements. “The Asia Pacific market to grow at the highest CAGR during the forecast period.” The clinical microbiology market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increase awareness related to human orgnaoids, supportive regulations for the development and commercialization of advanced human organoids products, rising healthcare expenditure, increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of transplants are the major factors driving the growth of the APAC human organoids market. Breakdown of supply-side primary interviews: • By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45% • By Designation: C-level: 30%, D-level: 29%, and Others: 47% • By Region: North America: 40%, Europe: 30%, APAC: 22%, Latin America: 6%, and the Middle East & Africa: 2% The major players operating in the human organoids market are BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands). Research Coverage This report studies the human organoids market based on the product, application, usabilty, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Key Benefits of Buying the Report This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the human organoids market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$4,950

Human Organoids Market by Product (Pancreas, Kidney, Lung, GIT, Liver Models) Usabilty (Customized, Ready-To-Use), Application (Toxicity, Pathology, Personalized & Regenerative Medicine), Enduser (Pharma-Biotech, CROs, Academia) - Global Forecast to 2025

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed